Repare Therapeutics Inc., a clinical-stage precision oncology company, announced the approval of the acquisition of all its common shares by XenoTherapeutics, Inc.
The approval was obtained at a special meeting of Shareholders with a high percentage of votes in favor of the Transaction.
The Arrangement is subject to court approval and other closing conditions, expected to be finalized by January 28, 2026.
Shareholder Approval
99.76% of Shareholders approved the acquisition at the special meeting.
Compensation Approval
99.34% of Shareholders approved the compensation for named executive officers related to the Arrangement.
Liquidation Resolution
Shareholders approved the voluntary dissolution of the Company if the Arrangement is terminated.
Court Approval Pending
The Arrangement is subject to approval by the Superior Court of Québec, with a hearing scheduled for January 23, 2026.
- The approval marks a significant step towards the completion of the acquisition process.
- Once finalized, the acquisition by XenoTherapeutics, Inc. is expected to enhance Repare Therapeutics' position in the precision oncology sector.
With the shareholder approval secured, Repare Therapeutics is on track to consolidate its position through the acquisition by XenoTherapeutics, Inc.